Remove bristol-myers-wins-apellis-loses-busy-week-europes-drug-regulator
article thumbnail

Bristol Myers wins, Apellis loses in busy week at Europe's drug regulator

Fierce Pharma

Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of a marketing authorization | Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of marketing authorization for Apellis’ geographic atrophy (GA) drug Syfovre (pegcetacoplan injection), the company said it will (..)

Medicine 229